Judge's ruling against gene patents rocks genetics industry

A federal judge has invalidated the patents obtained for two key genes involved in breast and ovarian cancer, striking at the intellectual property foundation beneath the multibillion-dollar industry built up around genetic research. Judge Robert Sweet concluded that the patents on the BRCA1 and BRCA2 genes--held by Myriad Genetics and the University of Utah Research Foundation--were not valid, saying that the gene patents simply circumvented a prohibition against patenting human DNA. Report

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.